Early Tuesday, Karyopharm Therapeutics Inc. officials shook off the previous disappointment of lead agent selinexor in acute myeloid leukemia and turned to top-line findings from the phase IIb STORM (Selinexor Treatment of Refractory Myeloma) study. Tested in heavily pretreated patients with refractory multiple myeloma (MM), the oral selective inhibitor of nuclear export (SINE) hit its primary endpoint, achieving a 25.4 percent overall response rate (ORR), including two complete responses (CRs) and 29 partial (PRs) or very good partial responses (VGPRs) in patients with penta-refractory myeloma.